» Articles » PMID: 39019722

Breastfeeding, Growth, and Lung Disease in the First 3 Years of Life in Children with Cystic Fibrosis

Overview
Journal J Cyst Fibros
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2024 Jul 17
PMID 39019722
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The 2009 cystic fibrosis (CF) infant care guidelines recommend breastmilk as the initial feeding but do not address if/when it should be fortified or supplemented with formula to promote optimal growth and pulmonary health.

Methods: We conducted a prospective multi-center cohort study in breastfed and formula-fed infants that included 172 infants with CF who were born during 2012-17, enrolled after newborn screening at age 1.9 ± 1.0 months, and evaluated growth and lung disease manifestations in the first 3 years of life.

Results: Seventy-two percent of our study cohort was breastfed at birth, but 64 % transitioned to receiving fortified feedings (breastmilk, formula, or a combination) by 6 months of age to reverse the downward trajectory of their growth curves. Fortified feedings accelerated catch-up growth to normal weight-for-age (0.12 ± 0.80 z-score) and near normal height-for-age (-0.13 ± 0.90 z-score) at 3 years of age. Within the fortified group, breastmilk and formula were similarly effective in promoting catch-up growth, but proportionately fewer infants with CF fed predominantly breastmilk (30 %) experienced severe or moderate early-onset lung disease compared to those fed predominantly formula (62 %), p = 0.02.

Conclusions: Most infants with CF require fortified feedings to recuperate from growth faltering and achieve normal growth at 3 years of age. For these infants, the proactive/preventive strategy of fortified breastmilk feedings starting soon after CF diagnosis, an alternative to the reactive/monitoring approach, can minimize the risk of prolonged postnatal growth faltering, accelerate the potential of attaining catch-up growth, and decrease the likelihood of experiencing more severe early-onset lung disease.

Citing Articles

The Frequency and Potential Implications of HFE Genetic Variants in Children With Cystic Fibrosis.

Huang L, Lai H, Furuya K, Antos N, Asfour F, Boyne K Pediatr Pulmonol. 2025; 60(3):e71042.

PMID: 40071665 PMC: 11898569. DOI: 10.1002/ppul.71042.


Impact of acid blocker therapy on growth, gut microbiome, and lung disease in young children with cystic fibrosis.

Liu C, Bach T, Farrell P, Pavelec D, Antos N, Rock M J Pediatr Gastroenterol Nutr. 2024; 79(6):1124-1133.

PMID: 39465618 PMC: 11615133. DOI: 10.1002/jpn3.12389.

References
1.
Borowitz D, Robinson K, Rosenfeld M, Davis S, Sabadosa K, Spear S . Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155(6 Suppl):S73-93. PMC: 6324931. DOI: 10.1016/j.jpeds.2009.09.001. View

2.
. Breastfeeding and the use of human milk. Pediatrics. 2012; 129(3):e827-41. DOI: 10.1542/peds.2011-3552. View

3.
Jadin S, Wu G, Zhang Z, Shoff S, Tippets B, Farrell P . Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program. Am J Clin Nutr. 2011; 93(5):1038-47. PMC: 3076655. DOI: 10.3945/ajcn.110.004119. View

4.
Zemanick E, Taylor-Cousar J, Davies J, Gibson R, Mall M, McKone E . A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele. Am J Respir Crit Care Med. 2021; 203(12):1522-1532. PMC: 8483230. DOI: 10.1164/rccm.202102-0509OC. View

5.
Koscik R, Farrell P, Kosorok M, Zaremba K, Laxova A, Lai H . Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics. 2004; 113(6):1549-58. DOI: 10.1542/peds.113.6.1549. View